Time for changing coagulation management in trauma-related massive bleeding

Current Opinion in Anaesthesiology

Volumn 22, Issue 2, 2009, Pages 267-274

  Fries, Dietmar ^a   Innerhofer, Petra ^a   Schobersberger, Wolfgang ^b  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b Inst Emergency and Disaster Med   (Austria)

Author keywords

Blood transfusion; Coagulation; Coagulation factor concentrates; Massive bleeding; Thrombelastography and thrombelastometry

Indexed keywords

APROTININ; BLOOD CLOTTING FACTOR 13; BLOOD CLOTTING FACTOR CONCENTRATE; FIBRINOGEN; FRESH FROZEN PLASMA; INFUSION FLUID; PROTEIN C; PROTHROMBIN COMPLEX; RECOMBINANT BLOOD CLOTTING FACTOR 7A; THROMBOCYTE CONCENTRATE; TRANEXAMIC ACID;

ACIDOSIS; ANEMIA; AWARENESS; BLEEDING; BLOOD CLOTTING DISORDER; CLINICAL FEATURE; CONTINUOUS INFUSION; DISEASE SEVERITY; FIBRINOLYSIS; HEALTH EDUCATION; HEMODILUTION; HEMOSTASIS; HUMAN; HYPOCALCEMIA; HYPOTHERMIA; HYPOVOLEMIA; INJURY; PATIENT CARE; PRIORITY JOURNAL; REVIEW; THROMBOCYTE TRANSFUSION; VISCOELASTICITY;

ACIDOSIS; ANEMIA; BLOOD COAGULATION DISORDERS; BLOOD COAGULATION FACTORS; FACTOR VIIA; FACTOR XIII; FIBRINOGEN; HEMODILUTION; HUMANS; HYPOCALCEMIA; HYPOTHERMIA; PLASMA; PLATELET TRANSFUSION; RECOMBINANT PROTEINS; RISK FACTORS; WOUNDS AND INJURIES;

EID: 68049142042     PISSN: 09527907     EISSN: None     Source Type: Journal    
DOI: 10.1097/ACO.0b013e32832678d9     Document Type: Review

References (102)

1. Robinson WP 3rd, Ahn J, Stiffler A, et al. Blood transfusion is an independent predictor of increased mortality in nonoperatively managed blunt hepatic and splenic injuries. J Trauma 2005; 58:437-444; discussion 444-435.
2. Malone DL, Dunne J, Tracy JK, et al. Blood transfusion, independent of shock severity, is associated with worse outcome in trauma. J Trauma 2003; 54:898-905; discussion 905-897.
3. Niles SE, McLaughlin DF, Perkins JG, et al. Increased mortality associated with the early coagulopathy of trauma in combat casualties. J Trauma 2008; 64:1459-1463; discussion 1463-1455.
4. Martinowitz U, Michaelson M. Guidelines for the use of recombinant activated factor VII (rFVIIa) in uncontrolled bleeding: a report by the Israeli Multidisciplinary rFVIIa Task Force. J Thromb Haemost 2005; 3:640-648.
5. Mosseson MW. Fibrinogen and fibrin structure and functions. J Thromb Hemost 2005; 3:1894-1904.
6. Lorand L. Factor XIII: structure, activation, and interactions with fibrinogen and fibrin. Ann N Y Acad Sci 2001; 936:291-311.
7. Rojkjaer LP, Rojkjaer R. Clot stabilization for the prevention of bleeding. Hematol Oncol Clin North Am 2007; 21:25-32. This article summarizes mechanisms of thrombin-induced activation of factor XIII and TAFI, both important for stability of the formed clot.
8. Luddington RJ. Thrombelastography/thromboelastometry. Clin Lab Haematol 2005; 27:81-90.
9. Levrat A, Gros A, Rugeri L, et al. Evaluation of rotation thrombelastography for the diagnosis of hyperfibrinolysis in trauma patients. Br J Anaesth 2008; 100:792-797.
10. Rugeri L, Levrat A, David JS, et al. Diagnosis of early coagulation abnormalities in trauma patients by rotation thrombelastography. J Thromb Haemost 2007; 5:289-295.
11. Martini WZ, Cortez DS, Dubick MA, et al. Thrombelastography is better than PT, aPTT, and activated clotting time in detecting clinically relevant clotting abnormalities after hypothermia, hemorrhagic shock and resuscitation in pigs. J Trauma 2008; 65:535-543.
12. Plotkin AJ, Wade CE, Jenkins DH, et al. A reduction in clot formation rate and strength assessed by thrombelastography is indicative of transfusion requirements in patients with penetrating injuries. J Trauma 2008; 64:S64-S68.
13. Innerhofer P. Perioperative management of coagulation. Hamostaseologie 2006; 26:S3-S14.
14. Mittermayr M, Streif W, Haas T, et al. Hemostatic changes after crystalloid or colloid fluid administration during major orthopedic surgery: the role of fibrinogen administration. Anesth Analg 2007; 105:905-917. This extensive study analyzes hemostatic changes during surgery of the spine and randomized volume regimens using crystalloids or colloids. This is the first clinical study confirming results of earlier in-vitro and experimental studies showing the impact of colloids on fibrin polymerization and the administration of fibrinogen concentrate as a possible therapeutic approach. The study was also the first one to show that similar fibrinogen concentrations may result in very different clot strengths.
15. Brohi K, Singh J, Heron M, et al. Acute traumatic coagulopathy. J Trauma 2003; 54:1127-1130.
16. Hess JR. Blood and coagulation support in trauma care. Hematol Am Soc Hematol Educ Program 2007; 2007:187-191. An excellent review about the mechanisms of TIC, which clearly shows that the pathophysiology of TIC is distinctly different from DIC.
17. ••].
18. ••].
19. ••] impressively demonstrates that in injured patients, and also those exhibiting traumatic brain injury, consumption and dilution are not the main underlying mechanisms of TIC. Instead, their work indicates that the presence of hypoperfusion (base deficit > 6) triggers systemic endogenous anticoagulation by activating the thrombomodulin-protein C pathway, resulting in increased fibrinolysis. These results underscore the importance of avoiding hypovolemia by adequate fluid management.
20. Schierhout G, Roberts I. Fluid resuscitation with colloid or crystalloid solutions in critically ill patients: a systematic review of randomised trials. BMJ 1998; 316:961-964.
21. Choi PT, Yip G, Quinonez LG, et al. Crystalloids vs. colloids in fluid resuscitation: a systematic review. Crit Care Med 1999; 27:200-210.
22. Chappell D, Jacob M, Hofmann-Kiefer K, et al. A rational approach to perioperative fluid management. Anesthesiology 2008; 109:723-740. This is an outstanding review about the principal side effects of fluid therapy, emphasizing a rational approach according to the actual needs of the individual patient and keeping in mind the difference between the need for fluid and volume replacement.
23. Kiraly LN, Differding JA, Enomoto TM, et al. Resuscitation with normal saline (NS) vs. lactated ringers (LR) modulates hypercoagulability and leads to increased blood loss in an uncontrolled hemorrhagic shock swine model. J Trauma 2006; 61:57-64; discussion 64-55.
24. Knotzer H, Pajk W, Maier S, et al. Comparison of lactated Ringer's, gelatine and blood resuscitation on intestinal oxygen supply and mucosal tissue oxygen tension in haemorrhagic shock. Br J Anaesth 2006; 97:509-516.
25. Haas T, Fries D, Holz C, et al. Less impairment of hemostasis and reduced blood loss in pigs after resuscitation from hemorrhagic shock using the small-volume concept with hypertonic saline/hydroxyethyl starch as compared to administration of 4% gelatin or 6% hydroxyethyl starch solution. Anesth Analg 2008; 106:1078-1086.
26. Treib J, Baron JF, Grauer MT, et al. An international view of hydroxyethyl starches. Intensive Care Med 1999; 25:258-268.
27. Avorn J, Patel M, Levin R, et al. Hetastarch and bleeding complications after coronary artery surgery. Chest 2003; 124:1437-1442.
28. Fries D, Innerhofer P, Klingler A, et al. The effect of the combined administration of colloids and lactated Ringer's solution on the coagulation system: an in vitro study using thromboelastograph coagulation analysis (ROTEG). Anesth Analg 2002; 94:1280-1287.
29. Fries D, Innerhofer P, Reif C, et al. The effect of fibrinogen substitution on reversal of dilutional coagulopathy: an in vitro model. Anesth Analg 2006; 102:347-351.
30. Innerhofer P, Fries D, Margreiter J, et al. The effects of perioperatively administered colloids and crystalloids on primary platelet-mediated hemostasis and clot formation. Anesth Analg 2002; 95:858-865.
31. De Lorenzo C, Calatzis A, Welsch U, et al. Fibrinogen concentrate reverses dilutional coagulopathy induced in vitro by saline but not by hydroxyethyl starch 6%. Anesth Analg 2006; 102:1194-1200.
32. Kermode JC, Zheng Q, Milner EP. Marked temperature dependence of the platelet calcium signal induced by human von Willebrand factor. Blood 1999; 94:199-207.
33. Wolberg AS, Meng ZH, Monroe DM 3rd, et al. A systematic evaluation of the effect of temperature on coagulation enzyme activity and platelet function. J Trauma 2004; 56:1221-1228.
34. Watts DD, Trask A, Soeken K, et al. Hypothermic coagulopathy in trauma: effect of varying levels of hypothermia on enzyme speed, platelet function, and fibrinolytic activity. J Trauma 1998; 44:846-854.
35. Martini WZ. The effects of hypothermia on fibrinogen metabolism and coagulation function in swine. Metabolism 2007; 56:214-221. This experimental work clarifies that hypothermia not only provokes delay of thrombin generation but also decreases fibrinogen synthesis.
36. Martini WZ, Pusateri AE, Uscilowicz JM, et al. Independent contributions of hypothermia and acidosis to coagulopathy in swine. J Trauma 2005; 58:1002-1009.
37. Straub A, Breuer M, Wendel HP, et al. Critical temperature ranges of hypothermia-induced platelet activation: possible implications for cooling patients in cardiac surgery. Thromb Haemost 2007; 97:608-616.
38. Dirkmann D, Hanke AA, Gorlinger K, et al. Hypothermia and acidosis synergistically impair coagulation in human whole blood. Anesth Analg 2008; 106:1627-1632. This is the only in-vitro study assessing synergistically the effects of hypothermia and acidosis after an incubation time of 30 min and referring to clinically relevant pH values of 7.0-7.3. Results show that, at these pH values, acidosis per se did not influence clot formation unless combined with hypothermia.
39. Martini WZ, Holcomb JB. Acidosis and coagulopathy: the differential effects on fibrinogen synthesis and breakdown in pigs. Ann Surg 2007; 246:831-835. This study shows that, besides hypothermia, acidosis also interferes with fibrinogen's availability by increasing its breakdown.
40. Martini WZ, Dubick MA, Pusateri AE, et al. Does bicarbonate correct coagulation function impaired by acidosis in swine? J Trauma 2006; 61:99-106.
41. Martini WZ, Dubick MA, Wade CE, et al. Evaluation of tris-hydroxymethylaminomethane on reversing coagulation abnormalities caused by acidosis in pigs. Crit Care Med 2007; 35:1568-1574. This study confirms the earlier finding of the authors that acidosis-related decreased thrombin generation recovers spontaneously not only during administration of Ringer's lactated solution but also with THAM. Results also show that clot formation remained impaired through the acidosis-related loss of fibrinogen and platelets.
42. Meng ZH, Wolberg AS, Monroe DM 3rd, et al. The effect of temperature and pH on the activity of factor VIIa: implications for the efficacy of high-dose factor VIIa in hypothermic and acidotic patients. J Trauma 2003; 55:886-891.
43. Engstrom M, Schott U, Nordstrom CH, et al. Increased lactate levels impair the coagulation system: a potential contributing factor to progressive hemorrhage after traumatic brain injury. J Neurosurg Anesthesiol 2006; 18:200-204.
44. Lier H, Krep H, Schroeder S, et al. Preconditions of hemostasis in trauma: a review. The influence of acidosis, hypocalcemia, anemia, and hypothermia on functional hemostasis in trauma. J Trauma 2008; 65:951-960. This is an excellent review about factors contributing to development of TIC. Underlying mechanisms and therapeutic options are discussed in detail.
45. Dunne JR, Riddle MS, Danko J, et al. Blood transfusion is associated with infection and increased resource utilization in combat casualties. Am Surg 2006; 72:619-625; discussion 625-616.
46. Hebert PC, Wells G, Blajchman MA, et al. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group. N Engl J Med 1999; 340:409-417.
47. McIntyre L, Hebert PC, Wells G, et al. Is a restrictive transfusion strategy safe for resuscitated and critically ill trauma patients? J Trauma 2004; 57:563-568; discussion 568.
48. Hardy JF, de Moerloose P, Samama CM. Massive transfusion and coagulopathy: pathophysiology and implications for clinical management. Can J Anaesth 2006; 53:S40-S58.
49. Practice guidelines for perioperative blood transfusion and adjuvant therapies: an updated report by the American Society of Anesthesiologists Task Force on Perioperative Blood Transfusion and Adjuvant Therapies. Anesthesiology 2006; 105:198-208.
50. Spahn DR, Cerny V, Coats TJ, et al. Management of bleeding following major trauma: a European guideline. Crit Care 2007; 11:R17. This article provides an extensive review on all aspects of trauma care and also considers new concepts such as administration of fibrinogen concentrate for treatment of acquired hypofibrinogenemia.
51. Velik-Salchner C, Haas T, Innerhofer P, et al. The effect of fibrinogen concentrate on thrombocytopenia. J Thromb Haemost 2007; 5:1019-1025. Although it was an experimental study and used huge dosages of fibrinogen concentrate, this study, for the first time, showed in vivo that strong fibrinogen/fibrin polymerization can compensate for thrombocytopenia-related reduction of clot firmness and associated bleeding tendency.
52. Khan H, Belsher J, Yilmaz M, et al. Fresh-frozen plasma and platelet transfusions are associated with development of acute lung injury in critically ill medical patients. Chest 2007; 131:1308-1314.
53. Hiippala ST, Myllyla GJ, Vahtera EM. Hemostatic factors and replacement of major blood loss with plasma-poor red cell concentrates. Anesth Analg 1995; 81:360-365.
54. McLoughlin TM, Fontana JL, Alving B, et al. Profound normovolemic hemodilution: hemostatic effects in patients and in a porcine model. Anesth Analg 1996; 83:459-465.
55. Martini WZ, Chinkes DL, Pusateri AE, et al. Acute changes in fibrinogen metabolism and coagulation after hemorrhage in pigs. Am J Physiol Endocrinol Metab 2005; 289:E930-E934.
56. Singbartl K, Innerhofer P, Radvan J, et al. Hemostasis and hemodilution: a quantitative mathematical guide for clinical practice. Anesth Analg 2003; 96:929-935.
57. O'Shaughnessy DF, Atterbury C, Bolton Maggs P, et al. Guidelines for the use of fresh-frozen plasma, cryoprecipitate and cryosupernatant. Br J Haematol 2004; 126:11-28.
58. Ciavarella D, Reed RL, Counts RB, et al. Clotting factor levels and the risk of diffuse microvascular bleeding in the massively transfused patient. Br J Haematol 1987; 67:365-368.
59. Weinstock N, Ntefidou M. SSC International Collaborative Study to establish the first high fibrinogen plasma reference material for use with different fibrinogen assay techniques. J Thromb Haemost 2006; 4:1825-1827.
60. Hiippala ST. Dextran and hydroxyethyl starch interfere with fibrinogen assays. Blood Coagul Fibrinolysis 1995; 6:743-746.
61. Blome M, Isgro F, Kiessling AH, et al. Relationship between factor XIII activity, fibrinogen, haemostasis screening tests and postoperative bleeding in cardiopulmonary bypass surgery. Thromb Haemost 2005; 93:1101-1107.
62. Charbit B, Mandelbrot L, Samain E, et al. The decrease of fibrinogen is an early predictor of the severity of postpartum hemorrhage. J Thromb Haemost 2007; 5:266-273. This study impressively demonstrates the role of fibrinogen in limiting blood loss.
63. Gerlach R, Tolle F, Raabe A, et al. Increased risk for postoperative hemorrhage after intracranial surgery in patients with decreased factor XIII activity: implications of a prospective study. Stroke 2002; 33:1618-1623.
64. Ucar HI, Oc M, Tok M, et al. Preoperative fibrinogen levels as a predictor of postoperative bleeding after open heart surgery. Heart Surg Forum 2007; 10:E392-E396.
65. Fenger-Eriksen C, Anker-Moller E, Heslop J, et al. Thrombelastographic whole blood clot formation after ex vivo addition of plasma substitutes: improvements of the induced coagulopathy with fibrinogen concentrate. Br J Anaesth 2005; 94:324-329.
66. Haas T, Fries D, Velik-Salchner C, et al. The in vitro effects of fibrinogen concentrate, factor XIII and fresh frozen plasma on impaired clot formation after 60% dilution. Anesth Analg 2008; 106:1360-1365. This is the first in-vitro study comparing the effects of fibrinogen, factor XIII and FFP in reversing dilution-dependent changes in clot formation. Results show that initiation of coagulation can be restored to baseline values with any of the substitutes except factor XIII. However, relevant recovery of clot firmness was only observed by using fibrinogen concentrate.
67. Fries D, Haas T, Klingler A, et al. Efficacy of fibrinogen and prothrombin complex concentrate used to reverse dilutional coagulopathy: a porcine model. Br J Anaesth 2006; 97:460-467.
68. Haas T, Fries D, Velik-Salchner C, et al. Fibrinogen in craniosynostosis surgery. Anesth Analg 2008; 106:725-731.
69. Danes AF, Cuenca LG, Bueno SR, et al. Efficacy and tolerability of human fibrinogen concentrate administration to patients with acquired fibrinogen deficiency and active or in high-risk severe bleeding. Vox Sang 2008; 94:221-226. This is an observational study of 81 patients receiving fibrinogen concentrate for treatment of various forms of acquired hypofibrinogenemia, reporting fibrinogen recovery, efficacy and relationship of posttreatment fibrinogen concentrations and survival.
70. Weinkove R, Rangarajan S. Fibrinogen concentrate for acquired hypofibrinogenaemic states. Transfus Med 2008; 18:151-157. In this observational study, fibrinogen concentrate was predominately administered to patients exhibiting extensive blood loss after conventional treatment with red cells, FFP, platelets and, in some patients, cryoprecipitate also. Results show that, in 46% of patients, fibrinogen administration alone stopped bleeding and the costs were comparable to that of cryoprecipitate.
71. Fries D, Krismer A, Klingler A, et al. Effect of fibrinogen on reversal of dilutional coagulopathy: a porcine model. Br J Anaesth 2005; 95:172-177.
72. Fenger-Eriksen C, Lindberg-Larsen M, Christensen AQ, et al. Fibrinogen concentrate substitution therapy in patients with massive haemorrhage and low plasma fibrinogen concentrations. Br J Anaesth 2008; 101:769-773. This observational study in 43 patients showed that after administration of fibrinogen concentrate results of coagulation tests improved and the need for transfusion of red cells, FFP and platelets decreased.
73. Stinger HK, Spinella PC, Perkins JG, et al. The ratio of fibrinogen to red cells transfused affects survival in casualties receiving massive transfusions at an army combat support hospital. J Trauma 2008; 64:S79-S85.
74. Samama CM. Prothrombin complex concentrates: a brief review. Eur J Anaesthesiol 2008; 25:784-789.
75. Pabinger-Fasching I. Warfarin-reversal: results of a phase III study with pasteurised, nanofiltrated prothrombin complex concentrate. Thromb Res 2008; 122 (Suppl 2):S19-S22.
76. Dickneite G, Doerr B, Kaspereit F. Characterization of the coagulation deficit in porcine dilutional coagulopathy and substitution with a prothrombin complex concentrate. Anesth Analg 2008; 106:1070-1077.
77. Chandler WL, Patel MA, Gravelle L, et al. Factor XIIIA and clot strength after cardiopulmonary bypass. Blood Coagul Fibrinolysis 2001; 12:101-108.
78. Wettstein P, Haeberli A, Stutz M, et al. Decreased factor XIII availability for thrombin and early loss of clot firmness in patients with unexplained intraoperative bleeding. Anesth Analg 2004; 99:1564-1569.
79. Martinowitz U, Kenet G, Segal E, et al. Recombinant activated factor VII for adjunctive hemorrhage control in trauma. J Trauma 2001; 51:431-438.
80. Boffard KD, Riou B, Warren B, et al. Recombinant factor VIIa as adjunctive therapy for bleeding control in severely injured trauma patients: two parallel randomized, placebo-controlled, double-blind clinical trials. J Trauma 2005; 59:8-15.
81. Hsia CC, Chin-Yee IH, McAlister VC. Use of recombinant activated factor VII in patients without hemophilia: a meta-analysis of randomized control trials. Ann Surg 2008; 248:61-68.
82. Narayan RK, Maas AI, Marshall LF, et al. Recombinant factor VIIA in traumatic intracerebral hemorrhage: results of a dose-escalation clinical trial. Neurosurgery 2008; 62:776-786.
83. Perkins JG, Schreiber MA, Wade CE, et al. Early versus late recombinant factor VIIa in combat trauma patients requiring massive transfusion. J Trauma 2007; 62:1095-1099.
84. Tanaka KA, Taketomi T, Szlam F, et al. Improved clot formation by combined administration of activated factor VII (NovoSeven) and fibrinogen (Haemocomplettan P). Anesth Analg 2008; 106:732-738. This in-vitro study demonstrates that, even in the presence of rFVIIa, the substrate fibrinogen determines the quality of clot formation. The study also shows that, in profibrinolytic states, rFVIIa itself accelerates fibrinolysis and that the combination with fibrinogen did not change clot lysis, which was inhibited only by aprotinin.
85. Casbard AC, Williamson LM, Murphy MF, et al. The role of prophylactic fresh frozen plasma in decreasing blood loss and correcting coagulopathy in cardiac surgery. A systematic review. Anaesthesia 2004; 59:550-558.
86. Stanworth SJ, Brunskill SJ, Hyde CJ, et al. Is fresh frozen plasma clinically effective? A systematic review of randomized controlled trials. Br J Haematol 2004; 126:139-152.
87. Chowdhury P, Saayman AG, Paulus U, et al. Efficacy of standard dose and 30 ml/kg fresh frozen plasma in correcting laboratory parameters of haemostasis in critically ill patients. Br J Haematol 2004; 125:69-73.
88. Etemadrezaie H, Baharvahdat H, Shariati Z, et al. The effect of fresh frozen plasma in severe closed head injury. Clin Neurol Neurosurg 2007; 109:166-171. This study shows undesired side effects of prophylactic FFP administration.
89. Hedin A, Hahn RG. Volume expansion and plasma protein clearance during intravenous infusion of 5% albumin and autologous plasma. Clin Sci (Lond) 2005; 108:217-224. Although it was published in 2005, this remains the only study in humans measuring volume expansion after administration of plasma and also measuring coagulation factors such as fibrinogen or antithrombin. Data show that the volume-expanding effects of approximately 1000 ml plasma exceed those of 5% albumin and explain the difficulty of increasing the concentration of any protein of interest by transfusing FFP.
90. Win N, Massey E, Lucas G, et al. Ninety-six suspected transfusion related acute lung injury cases: investigation findings and clinical outcome. Hematology 2007; 12:461-469.
91. Gajic O, Gropper MA, Hubmayr RD. Pulmonary edema after transfusion: how to differentiate transfusion-associated circulatory overload from transfusion-related acute lung injury. Crit Care Med 2006; 34:S109-S113.
92. Dara SI, Rana R, Afessa B, et al. Fresh frozen plasma transfusion in critically ill medical patients with coagulopathy. Crit Care Med 2005; 33:2667-2671.
93. Sarani B, Dunkman WJ, Dean L, et al. Transfusion of fresh frozen plasma in critically ill surgical patients is associated with an increased risk of infection. Crit Care Med 2008; 36:1114-1118.
94. Scalea TM, Bochicchio KM, Lumpkins K, et al. Early aggressive use of fresh frozen plasma does not improve outcome in critically injured trauma patients. Ann Surg 2008; 248:578-584.
95. Maegele M, Lefering R, Paffrath T, et al. Red-blood-cell to plasma ratios transfused during massive transfusion are associated with mortality in severe multiple injury: a retrospective analysis from the Trauma Registry of the Deutsche Gesellschaft fur Unfallchirurgie. Vox Sang 2008; 95:112-119.
96. Kashuk JL, Moore EE, Johnson JL, et al. Postinjury life threatening coagulopathy: is 1:1 fresh frozen plasma:packed red blood cells the answer? J Trauma 2008; 65:261-270.
97. Zufferey P, Merquiol F, Laporte S, et al. Do antifibrinolytics reduce allogeneic blood transfusion in orthopedic surgery? Anesthesiology 2006; 105:1034-1046.
98. Henry DA, Carless PA, Moxey AJ, et al. Antifibrinolytic use for minimising perioperative allogeneic blood transfusion. Cochrane Database Syst Rev 2007:CD001886.
99. Molenaar IQ, Warnaar N, Groen H, et al. Efficacy and safety of antifibrinolytic drugs in liver transplantation: a systematic review and meta-analysis. Am J Transplant 2007; 7:185-194.
100. Mangano DT, Tudor IC, Dietzel C. The risk associated with aprotinin in cardiac surgery. N Engl J Med 2006; 354:353-365.
101. Mangano DT, Miao Y, Vuylsteke A, et al. Mortality associated with aprotinin during 5 years following coronary artery bypass graft surgery. JAMA 2007; 297:471-479.
102. Fergusson DA, Hebert PC, Mazer CD, et al. A comparison of aprotinin and lysine analogues in high-risk cardiac surgery. N Engl J Med 2008; 358:2319-2331.